[go: up one dir, main page]

IN2014CH00062A - - Google Patents

Info

Publication number
IN2014CH00062A
IN2014CH00062A IN62CH2014A IN2014CH00062A IN 2014CH00062 A IN2014CH00062 A IN 2014CH00062A IN 62CH2014 A IN62CH2014 A IN 62CH2014A IN 2014CH00062 A IN2014CH00062 A IN 2014CH00062A
Authority
IN
India
Prior art keywords
compositions
optionally
carbapenem
stabilizer
therapy
Prior art date
Application number
Inventor
Alagarsamy Alagumurugan
Basak Sachinandan
Priya Shanmuga
Agrawal Sudeep
Louis Amari
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospira Inc filed Critical Hospira Inc
Priority to IN62CH2014 priority Critical patent/IN2014CH00062A/en
Priority to PCT/US2014/072996 priority patent/WO2015105720A1/en
Publication of IN2014CH00062A publication Critical patent/IN2014CH00062A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application provides stable compositions and methods of producing them. The composition comprises a carbapenem, a buffer, and a stabilizer. The compositions according to the invention are used in the treatment of bacterial infections and therapy. The compositions are suitable to be administered parenterally, optionally intramuscularly, optionally intravenously
IN62CH2014 2014-01-07 2014-12-31 IN2014CH00062A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN62CH2014 IN2014CH00062A (en) 2014-01-07 2014-12-31
PCT/US2014/072996 WO2015105720A1 (en) 2014-01-07 2014-12-31 Stabilised carbapenem compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN62CH2014 IN2014CH00062A (en) 2014-01-07 2014-12-31

Publications (1)

Publication Number Publication Date
IN2014CH00062A true IN2014CH00062A (en) 2015-07-10

Family

ID=53524262

Family Applications (1)

Application Number Title Priority Date Filing Date
IN62CH2014 IN2014CH00062A (en) 2014-01-07 2014-12-31

Country Status (2)

Country Link
IN (1) IN2014CH00062A (en)
WO (1) WO2015105720A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114224854A (en) * 2022-02-14 2022-03-25 成都晶富医药科技有限公司 Ertapenem for injection and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA62920C2 (en) * 1996-05-28 2004-01-15 Merck & Co Inc Carbapeneme antibiotic, a composition and a method for the preparation
CN102026621A (en) * 2008-05-15 2011-04-20 巴克斯特国际公司 Stable pharmaceutical formulations
CN102558182B (en) * 2010-12-31 2015-02-11 石药集团中奇制药技术（石家庄）有限公司 Ertapenem sodium crystal form E and preparation method thereof

Also Published As

Publication number Publication date
WO2015105720A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
PH12016501512A1 (en) Treatment for resistant acne
MX381456B (en) Transduction buffer
MX2018001075A (en) Antibacterial therapeutics and prophylactics.
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MX370792B (en) Methods and compositions for the treatment of cancer.
MX2017009720A (en) Oligosaccharide compositions for use in nutritional compositions, and methods of producing thereof.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018000715A (en) Methods for treating cancer using apilimod.
EA030204B8 (en) Isoindoline derivatives for use in the treatment of a viral infection
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX2015008486A (en) Compositions and methods for treating bacterial infections.
EP4342531A3 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
IN2014CH00062A (en)
WO2020022975A3 (en) New pharmaceutical compositions in the treatment of copd
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis